Aprogen Pharmaceuticals Inc Cash Flow Conversion Efficiency
Aprogen Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) has a cash flow conversion efficiency ratio of -0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-7.66 Billion ≈ $-5.19 Million USD) by net assets (₩315.16 Billion ≈ $213.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aprogen Pharmaceuticals Inc (2010–2024)
Cash flow conversion efficiency of Aprogen Pharmaceuticals Inc from 2010 to 2024. This chart illustrates how Aprogen Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 003060 stock price for real-time trading data and today's change.
Aprogen Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Aprogen Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aprogen Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aprogen Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market cap of Aprogen Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aplicaciones y Tratamiento de Sistemas S.A.
MC:ATSI
|
0.029x |
|
Patriot Acquisition Corp.
NASDAQ:PTAC
|
-0.003x |
|
Shin Ruenn Development Co Ltd
TWO:6186
|
0.299x |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
0.019x |
|
Sri Rejeki Isman(Sritex)PT
JK:SRIL
|
0.007x |
|
Datawalk SA
WAR:DAT
|
-1.044x |
|
Caisse Régionale de Crédit Agricole du Morbihan
PA:CMO
|
0.004x |
|
Thrace Plastics Holding and Commercial S.A
AT:PLAT
|
0.033x |
Annual Cash Flow Conversion Efficiency for Aprogen Pharmaceuticals Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Aprogen Pharmaceuticals Inc from 2010 to 2024. Review 003060 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩378.69 Billion ≈ $256.63 Million |
₩-31.00 Billion ≈ $-21.01 Million |
-0.082x | +10.32% |
| 2023-12-31 | ₩368.69 Billion ≈ $249.86 Million |
₩-33.65 Billion ≈ $-22.80 Million |
-0.091x | -281.07% |
| 2022-12-31 | ₩510.41 Billion ≈ $345.90 Million |
₩25.73 Billion ≈ $17.44 Million |
0.050x | +583.45% |
| 2021-12-31 | ₩597.18 Billion ≈ $404.70 Million |
₩-6.23 Billion ≈ $-4.22 Million |
-0.010x | -177.13% |
| 2020-12-31 | ₩598.36 Billion ≈ $405.50 Million |
₩8.09 Billion ≈ $5.48 Million |
0.014x | +558.38% |
| 2019-12-31 | ₩347.64 Billion ≈ $235.59 Million |
₩713.73 Million ≈ $483.69K |
0.002x | -76.79% |
| 2018-12-31 | ₩150.51 Billion ≈ $102.00 Million |
₩1.33 Billion ≈ $902.26K |
0.009x | +107.71% |
| 2017-12-31 | ₩77.86 Billion ≈ $52.77 Million |
₩-8.93 Billion ≈ $-6.05 Million |
-0.115x | -2090.66% |
| 2016-12-31 | ₩78.12 Billion ≈ $52.94 Million |
₩449.98 Million ≈ $304.95K |
0.006x | -78.87% |
| 2015-12-31 | ₩67.75 Billion ≈ $45.91 Million |
₩1.85 Billion ≈ $1.25 Million |
0.027x | +124.48% |
| 2014-12-31 | ₩62.11 Billion ≈ $42.09 Million |
₩-6.92 Billion ≈ $-4.69 Million |
-0.111x | -270.03% |
| 2013-12-31 | ₩56.55 Billion ≈ $38.32 Million |
₩-1.70 Billion ≈ $-1.15 Million |
-0.030x | -619.64% |
| 2010-12-31 | ₩42.81 Billion ≈ $29.01 Million |
₩247.92 Million ≈ $168.01K |
0.006x | -- |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.